

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001801917
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Roivant Sciences Ltd.
SEC File Number 001-40782
Address of Issuer c/o Roivant Sciences Ltd.
7th Floor, 50 Broadway
London
UNITED KINGDOM
SW1H 0DB
Phone 442074003347
Name of Person for Whose Account the Securities are To Be Sold Venker Eric

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer President & COO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common shares, \$0.0000000341740141 par value per share ("Common Shares")	E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	28936	283283.44	758427350	06/21/2023	The Nasdaq Global Ma

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	06/20/2023	Restricted Stock Units granted under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan	Roivant Sciences Ltd.	<input type="checkbox"/>		28936	06/20/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	03/23/2023	14194	103616.2
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	04/26/2023	72906	631675.25
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	04/27/2023	73514	625908.88
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	04/28/2023	75823	641877.24
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	05/01/2023	61155	525251.75
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	05/02/2023	109074	897477.32
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	05/03/2023	118760	997196.4
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	05/04/2023	88838	737504.16
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	05/08/2023	61206	546237.33

Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	05/09/2023 238724	2203422.52
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	05/23/2023 15671	150128.18
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	05/23/2023 415	4087.75
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	06/07/2023 201	1979.85
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	06/09/2023 299384	2966895.44

144: Remarks and Signature

Remarks The securities included in Table I represent a maximum number of shares that may be sold to cover the reporting person's tax obligations when restricted stock units belonging to the reporting person are settled. The securities reported in Table I do not represent discretionary trades by the reporting person, and will be sold, or were sold, as applicable, for the limited purpose of satisfying tax withholding obligations.. Table II does not include shares that were "net settled" by the Issuer in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units previously granted to the reporting person.

Date of Notice 06/21/2023

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 02/17/2022

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Eric Venker

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)